Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen.
Ya-Ping TuHendrik Maxime LagraauwMichael MethodYuemei WangEva HanzeLingling LiTimothy ParrottCallum M SlossEric H WestinPublished in: British journal of clinical pharmacology (2024)
The trough concentration of MIRV correlated with efficacy whereas the AUC of MIRV was associated with major AEs. The ER relationships supported the selected therapeutic dose regimen.
Keyphrases